Başlık için Bildiri Koleksiyonu listeleme
Toplam kayıt 515, listelenen: 322-341
-
National pediatric hematopoietic stem cell transplantation activity in Turkey
(Nature Publishing Group, 2015)... -
Neuromyelitis optica and neuromyelitis optica spectrum disorders: the evaluation of 86 patients followed by Istanbul Bilim University
(Sage Publications Ltd., 2014)… -
Neuromyelitis optica and neuromyelitis optica spectrum disorders: The evaluation of 86 patients followed by Istanbul Bilim University, department of neurology
(Sage PubLlications, 2015)Background and objectives: Neuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are relatively rare disorders. We aimed to evaluate clinical characteristics and disease course of the NMOSD patients followed at our ... -
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
(Ferrata Storti Foundation, 2017)… -
A novel candidate frameshift mutation for catecholaminergic polymorphic ventricular tchycardia
(Nature Publishing Group, 2019)... -
A novel missense KCNJ2 gene mutation associated with andersen tawil syndrome
(Nature Publishing Group, 2019)... -
A novel, on-demand therapy for premature ejaculation using a miniature trans-perineal electrical stimulator: A randomized-controlled trial
(Elsevier Science Ltd, 2022)... -
Objective evaluation of daily near activities distance in progressive myopic children
(Assoc Research Vision Ophthalmology Inc, 2019)... -
Objective measurement of photopic illuminance rate in daily life of progressive myopic children
(Assoc Research Vision Ophthalmology Inc, 2019)... -
Obstacle of physical activity and activities of daily living in patients with COPD: Dyspnea related kinesiophobia
(European Respiratory Society, 2019)--- -
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...